biostudies-literatureJain LNIA NIH HHSNINDS NIH HHS549-562https://www.ebi.ac.uk/biostudies/studies/S-EPMC10840643biostudies-literatureUnknown20(1)<h4>Introduction</h4>The National Institute on Aging - Alzheimer's Association (NIA-AA) ATN research framework proposes to use biomarkers for amyloid (A), tau (T), and neurodegeneration (N) to stage individuals with AD pathological features and track changes longitudinally. The overall aim was to utilize this framework to characterize pre-mortem ATN status longitudinally in a clinically diagnosed cohort of dementia with Lewy bodies (DLB) and to correlate it with the post mortem diagnosis.<h4>Methods</h4>The cohort was subtyped by cerebrospinal fluid (CSF) ATN category. A subcohort had longitudinal data, and a subgroup was neuropathologically evaluated.<h4>Results</h4>We observed a significant difference in Aβ_42/40 after 12 months in the A+T- group. Post mortem neuropathologic analyses indicated that most of the p-Tau 181 positive (T+) cases also had a high Braak stage.<h4>Discussion</h4>This suggests that DLB patients who are A+ but T- may need to be monitored to determine whether they remain A+ or ever progress to T positivity.<h4>Highlights</h4>Some A+T- DLB subjects transition from A+ to negative after 12-months. Clinically diagnosed DLB with LBP-AD (A+T+) maintain their positivity. Clinically diagnosed DLB with LBP-AD (A+T+) maintain their positivity. Monitoring of the A+T- sub-type of DLB may be necessary.Alzheimer's & dementia : the journal of the Alzheimer's AssociationATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium.PMC10840643U01 NS100610P30 AG062428R01 AG022304P30 AG066468R56 AG022304R56 AG063870P30 AG062429P30 AG072959Marder KSRao SLippa CFFormica SJain LPillai JAFleisher JEKhrestian MLopez OLTuason EDOguh OZabetian CPBerman SBGalvin JELitvan IIrwin DJHonig LSTsuang DWLeverenz JBBekris LMSabbagh MNTaylor ASGalasko DRBozoki ACfalseATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium.<h4>Introduction</h4>The National Institute on Aging - Alzheimer's Association (NIA-AA) ATN research framework proposes to use biomarkers for amyloid (A), tau (T), and neurodegeneration (N) to stage individuals with AD pathological features and track changes longitudinally. The overall aim was to utilize this framework to characterize pre-mortem ATN status longitudinally in a clinically diagnosed cohort of dementia with Lewy bodies (DLB) and to correlate it with the post mortem diagnosis.<h4>Methods</h4>The cohort was subtyped by cerebrospinal fluid (CSF) ATN category. A subcohort had longitudinal data, and a subgroup was neuropathologically evaluated.<h4>Results</h4>We observed a significant difference in Aβ_42/40 after 12 months in the A+T- group. Post mortem neuropathologic analyses indicated that most of the p-Tau 181 positive (T+) cases also had a high Braak stage.<h4>Discussion</h4>This suggests that DLB patients who are A+ but T- may need to be monitored to determine whether they remain A+ or ever progress to T positivity.<h4>Highlights</h4>Some A+T- DLB subjects transition from A+ to negative after 12-months. Clinically diagnosed DLB with LBP-AD (A+T+) maintain their positivity. Clinically diagnosed DLB with LBP-AD (A+T+) maintain their positivity. Monitoring of the A+T- sub-type of DLB may be necessary.2024-01-01T00:00:00Z2024 Jan2025-08-17T03:06:07.834Z2025-08-17T03:06:07.834ZS-EPMC108406433774092410.1002/alz.13398